Business
Moleculin Announces Dr. Hongbo Zhai Joins Science Advisory Board
To explore oncologic, dermatologic and viral opportunities for Moleculin's drug portfolio in China HOUSTON, March 10, 2020 /PRNewswire/ -- Moleculin Biotech,
About this update from Moleculin Biotech, Inc.
[{"type":"text","content":"To explore oncologic, dermatologic and viral opportunities for Moleculin's drug portfolio in China\n\n\nHOUSTON, March 10, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (\"Moleculin\" or the \"Company\"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced that Dr. Hongbo Zhai, former Senior Faculty and Supervisor of Postdoctoral Fellows at University of California San Francisco, has joined Moleculin's Science Advisory Board.\n\n \n \n \n \n \n \n\n \n\"We are honored to have Dr. Zhai, who brings two decades of research and development experience in pharmaceuticals and biotechnology, join our Science Advisory Board,\" commented Walter Klemp, Moleculin's Chairman and CEO. \"Dr. Zhai will be focused on identifying opportunities in oncology, dermatology, and virology within China for our three drug technologies. We look forward to building our business in China through Dr. Zhai's extensive network and relationships.\"\nAs a former board-certified dermatologist in China, Dr. Hongbo Zhai has extensive experience with Chinese regulatory authorities including the CFDA and the Ministry of Public Health. Dr. Zhai has contributed to the development of products in collaboration with global Fortune 500 companies such as Procter & Gamble, Pfizer, Johnson & Johnson, 3M Pharmaceuticals, and L'OREAL and has published more than 120 scientific articles in his research areas.\nAbout Moleculin Biotech, Inc.\nMoleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. The Company's clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug...